Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 1 Cushing Syndrome 1 ACTH Syndrome, Ectopic 1

Interventions

Specimen Handling 278 pembrolizumab 228 Magnetic Resonance Spectroscopy 228 Carboplatin 180 Biopsy 168 Cisplatin 166 Nivolumab 160 Cyclophosphamide 144 Radiotherapy 126 Paclitaxel 124 Gemcitabine 116 Bevacizumab 96 durvalumab 92 Dexamethasone 88 Rituximab 81 Oxaliplatin 80 venetoclax 75 atezolizumab 74 Capecitabine 71 Fluorouracil 70 Docetaxel 70 Doxorubicin 68 Etoposide 65 Radiosurgery 64 Ipilimumab 64 Radiation 62 Prednisone 61 Cytarabine 60 Lenalidomide 58 Pemetrexed 55

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × ASP3662 × 90 days × Clear all

NCT07296484 2026-05-12

CAPTAIN-T2D

Sparrow Pharmaceuticals

Phase 2 Recruiting

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡